Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$5.62
+1.0%
$5.58
$4.00
$7.54
$319.74M1.35994,809 shs2.92 million shs
FRMM
Forum Markets
$5.58
+7.3%
$4.73
$1.76
$174.60
$81.15M1.45288,232 shs419,739 shs
Organogenesis stock logo
ORGO
Organogenesis
$2.43
$2.46
$2.04
$7.08
$312.68M1.32706,680 shs2.84 million shs
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$5.75
+5.3%
$4.15
$1.91
$6.68
$308.28M0.63235,771 shs502,085 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
0.00%-2.69%-2.85%+30.89%-6.10%
FRMM
Forum Markets
0.00%+10.50%+30.68%+557,999,900.00%+557,999,900.00%
Organogenesis stock logo
ORGO
Organogenesis
0.00%-0.41%-7.25%+6.11%-31.36%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
0.00%+9.73%+23.39%+112.18%+10.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$5.62
+1.0%
$5.58
$4.00
$7.54
$319.74M1.35994,809 shs2.92 million shs
FRMM
Forum Markets
$5.58
+7.3%
$4.73
$1.76
$174.60
$81.15M1.45288,232 shs419,739 shs
Organogenesis stock logo
ORGO
Organogenesis
$2.43
$2.46
$2.04
$7.08
$312.68M1.32706,680 shs2.84 million shs
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$5.75
+5.3%
$4.15
$1.91
$6.68
$308.28M0.63235,771 shs502,085 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
0.00%-2.69%-2.85%+30.89%-6.10%
FRMM
Forum Markets
0.00%+10.50%+30.68%+557,999,900.00%+557,999,900.00%
Organogenesis stock logo
ORGO
Organogenesis
0.00%-0.41%-7.25%+6.11%-31.36%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
0.00%+9.73%+23.39%+112.18%+10.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
2.33
Hold$19.00238.38% Upside
FRMM
Forum Markets
2.50
Moderate Buy$10.0079.21% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.00
Hold$5.75136.63% Upside
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
2.33
Hold$8.0039.13% Upside

Current Analyst Ratings Breakdown

Latest FRMM, ABEO, ORGO, and TKNO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2026
FRMM
Forum Markets
UpgradeHold
5/28/2026
Organogenesis stock logo
ORGO
Organogenesis
Set Price Target$3.00
5/28/2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Reiterated RatingBuy$20.00
5/28/2026
Organogenesis stock logo
ORGO
Organogenesis
Initiated CoverageHold$3.00
5/15/2026
FRMM
Forum Markets
Boost Price TargetSpeculative Buy$5.00 ➝ $9.00
5/11/2026
FRMM
Forum Markets
Set Price Target$11.00
5/11/2026
Organogenesis stock logo
ORGO
Organogenesis
DowngradeHold (C)Sell (D)
5/11/2026
FRMM
Forum Markets
UpgradeStrong-Buy
5/8/2026
Organogenesis stock logo
ORGO
Organogenesis
DowngradeBuyNeutral
4/20/2026
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
Reiterated RatingSell (D-)
4/7/2026
FRMM
Forum Markets
Initiated CoverageSpeculative Buy$5.00
(Data available from 6/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$5.82M54.98N/AN/A$2.94 per share1.91
FRMM
Forum Markets
$6.55M12.39N/AN/A$12.59 per share0.44
Organogenesis stock logo
ORGO
Organogenesis
$564.17M0.55$0.65 per share3.75$2.36 per share1.03
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$40.52M7.61N/AN/A$1.28 per share4.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$71.18M$0.975.79N/AN/AN/A-53.98%-38.52%8/13/2026 (Estimated)
FRMM
Forum Markets
-$450.52M-$36.07N/A34.88N/AN/A-242.09%-135.46%N/A
Organogenesis stock logo
ORGO
Organogenesis
$37.03M-$0.19N/AN/AN/A-0.84%9.63%4.76%8/6/2026 (Estimated)
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$17.26M-$0.32N/AN/AN/A-41.07%-24.32%-16.34%8/6/2026 (Estimated)

Latest FRMM, ABEO, ORGO, and TKNO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
FRMM
Forum Markets
N/A-$3.64N/A-$3.58N/A$2.86 million
5/13/2026Q1 2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$0.33-$0.30+$0.03-$0.30$4.57 million$8.72 million
5/7/2026Q1 2026
Organogenesis stock logo
ORGO
Organogenesis
-$0.29-$0.37-$0.08-$0.44$43.26 million$37.23 million
5/6/2026Q1 2026
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$0.0926-$0.08+$0.0126-$0.08$10.23 million$11.08 million
3/31/2026Q4 2025
FRMM
Forum Markets
N/A-$12.14N/A-$12.24N/A$2.44 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
N/AN/AN/AN/AN/A
FRMM
Forum Markets
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
0.03
5.89
5.70
FRMM
Forum Markets
0.15
6.19
6.19
Organogenesis stock logo
ORGO
Organogenesis
0.05
3.53
3.16
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
0.20
4.59
3.60

Institutional Ownership

CompanyInstitutional Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
80.56%
FRMM
Forum Markets
4.07%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
13.81%

Insider Ownership

CompanyInsider Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
7.10%
FRMM
Forum Markets
15.10%
Organogenesis stock logo
ORGO
Organogenesis
18.80%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
12.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
9056.99 million52.95 millionOptionable
FRMM
Forum Markets
714.54 million12.35 millionN/A
Organogenesis stock logo
ORGO
Organogenesis
950128.68 million104.48 millionOptionable
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
24053.61 million46.91 millionNot Optionable

Recent News About These Companies

Alpha Teknova (NASDAQ:TKNO) Trading Down 1.5% - Here's Why
Alpha Teknova (TKNO) Q1 2026 Earnings Transcript
Teknova Reports First Quarter 2026 Financial Results
Alpha Teknova, Inc. (TKNO) Q4 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abeona Therapeutics stock logo

Abeona Therapeutics NASDAQ:ABEO

$5.62 +0.06 (+0.99%)
Closing price 06/26/2026 03:59 PM Eastern
Extended Trading
$5.62 0.00 (0.00%)
As of 06/26/2026 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Forum Markets NASDAQ:FRMM

$5.58 +0.38 (+7.31%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$5.53 -0.05 (-0.88%)
As of 06/26/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Forum Markets Inc is a digital asset platform modernizing capital markets through the tokenization of institutional-grade real-world assets on Ethereum. The company structures cash-generating assets on blockchain-based infrastructure to facilitate liquidity, investor access, and primary and secondary market activity. It combines traditional asset management practices with digital market infrastructure to support the origination, distribution, and trading of real-world assets.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$2.43 0.00 (0.00%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$2.42 -0.01 (-0.29%)
As of 06/26/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Alpha Teknova stock logo

Alpha Teknova NASDAQ:TKNO

$5.75 +0.29 (+5.31%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$5.78 +0.03 (+0.52%)
As of 06/26/2026 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.